Selectively Targeting Tumor Hypoxia With the Hypoxia-Activated Prodrug CP-506

Hypoxia-activated prodrugs (HAP) are a promising class of antineoplastic agents that can selectively eliminate hypoxic tumor cells. This study evaluates the hypoxia-selectivity and antitumor activity of CP-506, a DNA alkylating HAP with favorable pharmacologic properties. Stoichiometry of reduction,...

Descripción completa

Detalles Bibliográficos
Autores principales: van der Wiel, Alexander M.A., Jackson-Patel, Victoria, Niemans, Raymon, Yaromina, Ala, Liu, Emily, Marcus, Damiënne, Mowday, Alexandra M., Lieuwes, Natasja G., Biemans, Rianne, Lin, Xiaojing, Fu, Zhe, Kumara, Sisira, Jochems, Arthur, Ashoorzadeh, Amir, Anderson, Robert F., Hicks, Kevin O., Bull, Matthew R., Abbattista, Maria R., Guise, Christopher P., Deschoemaeker, Sofie, Thiolloy, Sophie, Heyerick, Arne, Solivio, Morwena J., Balbo, Silvia, Smaill, Jeff B., Theys, Jan, Dubois, Ludwig J., Patterson, Adam V., Lambin, Philippe
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Association for Cancer Research 2021
Materias:
Small Molecule Therapeutics
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9398139/
https://www.ncbi.nlm.nih.gov/pubmed/34625504
http://dx.doi.org/10.1158/1535-7163.MCT-21-0406

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9398139/
https://www.ncbi.nlm.nih.gov/pubmed/34625504
http://dx.doi.org/10.1158/1535-7163.MCT-21-0406

Ejemplares similares